Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: Experience of two cases

Haemophilia

Volumn 6, Issue 5, 2000, Pages 581-583

  Tagariello, G ^a   De Biasi, E ^a   Gajo, G B ^a   Risato, R ^a   Radossi, P ^a   Davoli, P G ^a   Traldi, A ^a  

^a Servizio Trasfusionale   (Italy)

Author keywords

Continuous infusion; Haemophilia; Inhibitors; RFVIIa

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; HEMOGLOBIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SODIUM CHLORIDE; TRANEXAMIC ACID;

ADULT; ARTHROPATHY; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONTINUOUS INFUSION; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG MEGADOSE; HEMOPHILIA A; HEMOSTASIS; HIP; HIP SURGERY; HUMAN; MALE; PRIORITY JOURNAL; THROMBOPHLEBITIS; TOTAL HIP PROSTHESIS;

ADULT; ARTHROPLASTY, REPLACEMENT, HIP; BLOOD LOSS, SURGICAL; CASE REPORT; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HEMOSTASIS; HUMAN; INFUSIONS, PARENTERAL; ISOANTIBODIES; MALE; RECOMBINANT PROTEINS; SODIUM CHLORIDE; TRANEXAMIC ACID;

EID: 0033832703     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2000.00400.x     Document Type: Article

References (9)

1. Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors: Benefits and limitations
2. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to FVIII. A Multicenter US Experience
3. Recombinant FVIIa for patients with inhibitors to FVIII or IX or FVII deficiency
4. Prospective randomized trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery
5. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in the Netherlands and Belgium
6. Two cases of total hip replacement performed under treatment with recombinant factor VIIa
7. Feasibility of using recombinant FVIIa in continuous infusion
8. Safety, efficacy and lessons from continuous infusion with rFVIIa
9. Experiences with continuous infusion of recombinant activated factor VII